Are intranasal corticosteroids all equally consistent in managing ocular symptoms of seasonal allergic rhinitis?

Current Medical Research and Opinion

Volumn 25, Issue 8, 2009, Pages 2021-2041

  Keith, Paul K ^a,c   Scadding, Glenis K ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b ROYAL NATIONAL THROAT NOSE AND EAR HOSPITAL   (United Kingdom)

^c Department of Medicine   (Canada)

Author keywords

Intranasal corticosteroids; Nasal; Ocular; Seasonal allergic rhinitis (SAR); Symptoms

Indexed keywords

AZELASTINE; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CICLESONIDE; CORTICOSTEROID; FLUNISOLIDE; FLUTICASONE FUROATE; FLUTICASONE PROPIONATE; LEVOCABASTINE; LORATADINE; MOMETASONE FUROATE; NOSE SPRAY; PLACEBO; TRIAMCINOLONE ACETONIDE;

CLINICAL TRIAL; DATA BASE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HAY FEVER; HEALTH CARE COST; HUMAN; RAGWEED; RATING SCALE; REVIEW; SCORING SYSTEM; SINGLE DRUG DOSE; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; ADRENAL CORTEX HORMONES; CHILD; EYE; FEMALE; HUMANS; MALE; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME;

EID: 67651007852     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903094106     Document Type: Review

References (74)

1. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63:8-160
2. Ciprandi G, Passalacqua G. Emerging anti-inflammatory agents for allergic rhinitis. Expert Opin Emerg Drugs 2005;10:689-705
3. Canonica GW, Bousquet J, Mullol J, et al. A survey of the burden of allergic rhinitis in Europe. Allergy 2007;62(Suppl 85):17-25
4. Ciprandi G, Cirillo I, Vizzaccaro A, et al. Seasonal and perennial allergic rhinitis: is this classification adherent to real life? Allergy 2005;60:882-7
5. Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc 2007;28:3-9
6. Blaiss MS. Allergic rhinoconjunctivitis: burden of disease. Allergy Asthma Proc 2007;28:393-7
7. Scadding GK, Williams A. The burden of allergic rhinitis as reported by UK patients compared with their doctors. Rhinology 2008;46:99-106
8. Leynaert B, Neukirch C, Liard R, et al. Quality of life in allergic rhinitis and asthma. A population-based study of young adults. Am J Respir Crit Care Med 2000;162:1391-6
9. Meltzer EO, Nathan RA, Selner JC, et al. Quality of life and rhinitic symptoms: Results of a nationwide survey with the SF-36 and RQLQ questionnaires. J Allergy Clin Immunol 1997;99:S815-19
10. Pratt EL, Craig TJ. Assessing outcomes from the sleep disturbance associated with rhinitis. Curr Opin Allergy Clin Immunol 2007;7:249-56
11. Walker S, Khan-Wasti S, Fletcher M, et al. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: Case-control study. J Allergy Clin Immunol 2007;120:381-7
12. Nihlen U, Greiff L, Montnemery P, et al. Incidence and remission of self-reported allergic rhinitis symptoms in adults. Allergy 2006;61:1299-304
13. European Federation of Allergy and Airway Diseases Patient Association. Results of the patient voice allergy survey: Impact of allergic rhinitis in Europe. Summary report. Available at: http://www.efanet.org/enews/documents/ AllergysummaryreportFINALdata220605-onsitea.doc. 2005
14. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 1998;81:478-518
15. Task Force on Allergic Disorders. The Allergy Report. Volume 1. 2000. Milwaukee, WI, American Academy of Allergy, Asthma and Immunology. Available at: http://www.theallergyreport.com. [Last accessed 21 June 2007]
16. Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ 1998;317:1624-9
17. Loth S, Bende M. Effect of nasal anaesthesia on lacrimal function after nasal allergen challenge. Clin Exp Allergy 1994; 24:375-6
18. Sheahan P, Walsh RM, Walsh MA, et al. Induction of nasal hyper-responsiveness by allergen challenge in allergic rhinitis: the role of afferent and efferent nerves. Clin Exp Allergy 2005;35:45-51
19. Baroody FM, Foster KA, Markaryan A, et al. Nasal ocular reflexes and eye symptoms in patients with allergic rhinitis. Ann Allergy Asthma Immunol 2008;100:194-9
20. Naclerio RM, Pinto J, deTineo M, et al. Elucidating the mechanism underlying the ocular symptoms associated with allergic rhinitis. Allergy Asthma Proc 2008;29:24-8
21. Baroody FM, Shenaq D, deTineo M, et al. Fluticasone furoate nasal spray reduces the nasal-ocular reflex: a mechanism for the efficacy of topical steroids in controlling allergic eye symptoms. J Allergy Clin Immunol 2009;123:1342-8
22. Naclerio R. Intranasal corticosteroids reduce ocular symptoms associated with allergic rhinitis. Otolaryngol Head Neck Surg 2008;138:129-39
23. Blaiss MS. Evolving paradigm in the management of allergic rhinitis-associated ocular symptoms: role of intranasal corticosteroids. Curr Med Res Opin 2008;24:821-36
24. Bielory L. Intranasal corticosteroids reduce ocular symptoms of allergic rhinitis as a class effect. J Allergy Clin Immunol 2008; 121:538-9
25. AstraZeneca. Trial number: 05-3011; Available at: www.fda. gov./cder/approval/index.htm. [Last accessed 24 April 2009]
26. Newson-Smith G, Powell M, Baehre M, et al. A placebo controlled study comparing the efficacy of intranasal azelastine and beclomethasone in the treatment of seasonal allergic rhinitis. Eur Arch Otorhinolaryngol 1997;254:236-41
27. AstraZeneca. Trial number: 05-3006; Available at: www.fda. gov./cder/approval/index.htm. [Last accessed 24 April 2009]
28. AstraZeneca. Trial number: 05-3030; Available at: www.fda. gov./cder/approval/index.htm. [Last accessed 24 April 2009]
29. Stern MA, Dahl R, Nielsen LP, et al. A comparison of aqueous suspensions of budesonide nasal spray (128 micrograms and 256 micrograms once daily) and fluticasone propionate nasal spray (200 micrograms once daily) in the treatment of adult patients with seasonal allergic rhinitis. Am J Rhinol 1997; 11:323-30
30. Ciprandi G, Canonica WG, Grosclaude M, et al. Effects of budesonide and fluticasone propionate in a placebo-controlled study on symptoms and quality of life in seasonal allergic rhinitis. Allergy 2002;57:586-91
31. AstraZeneca. Trial number: 05-3038; Available at: www.fda. gov./cder/approval/index.htm. [Last accessed 24 April 2009]
32. Andersson M, Lindqvist N, Svensson C, et al. Dry powder inhalation of budesonide in allergic rhinitis. Clin Otolaryngol Allied Sci 1993;18:30-3
33. Ratner PH, Wingertzahn MA, van Bavel JH, et al. Efficacy and safety of ciclesonide nasal spray for the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2006;118:1142-8
34. Fokkens WJ, Jogi R, Reinartz S, et al. Once daily fluticasone furoate nasal spray is effective in seasonal allergic rhinitis caused by grass pollen. Allergy 2007;62:1078-84
35. Kaiser HB, Naclerio RM, Given J, et al. Fluticasone furoate nasal spray: a single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 2007;119:1430-7
36. Jacobs R, Martin B, Hampel F, et al. Effectiveness of fluticasone furoate 110 μg once daily in the treatment of nasal and ocular symptoms of seasonal allergic rhinitis in adults and adolescents sensitized to mountain cedar pollen. Curr Med Res Opin 2009;25:1393-401
37. Martin BG, Ratner PH, Hampel FC, et al. Optimal dose selection of fluticasone furoate nasal spray for the treatment of seasonal allergic rhinitis in adults and adolescents. Allergy Asthma Proc 2007;28:216-25
38. Andrews CP, Martin BG, Jacobs RL, et al. Fluticasone furoate nasal spray is more effective than fexofenadine for nighttime symptoms of seasonal allergy. Allergy Asthma Proc 2009;30:128-38
39. Amar NJ, Kaiser H, Vandewalker M, et al. Fluticasone furoate nasal spray provides better relief from the nighttime symptoms of seasonal allergic rhinitis (SAR) than oral fexofenadine. Presented at the American College of Allergy, Asthma & Immunology Annual Meeting, Seattle, WA, November 6-11, 2008
40. Naclerio R, Kaiser H, Lumry W, et al. Fluticasone furoate nasal spray provided 24-hour relief of nasal and ocular symptoms of seasonal allergic rhinitis (SAR) caused by ragweed. Presented at the XXVI Congress of the European Academy of Allergology and Clinical Immunology, Göteborg, Sweden, June 9-13, 2007;Abstract 353
41. Stricker WE, Nathan RA, Winder JA, et al. Fluticasone propionate aqueous nasal spray (FP) and loratadine (LOR), alone and in combination, in the treatment of fall seasonal allergic rhinitis (SAR). Ann Allergy Asthma Immunol 1998;80:115
42. van Bavel JH, Ratner PH, Nayak AS, et al. Ocular efficacy and clinician overall evaluation of intranasal fluticasone propionate (FP) versus loratadine (LOR) in seasonal allergic rhinitis (SAR). Ann Allergy Asthma Immunol 1997;78:128
43. GlaxoSmithKline. Trial number: FLN-305; Available at: www.clinicalstudyresults.org. [Last accessed 24 April 2009]
44. GlaxoSmithKline. Trial number: FNM30034; Available at: www.clinicalstudyresults.org. [Last accessed 24 April 2009]
45. Bernstein DI, Levy AL, Hampel FC, et al. Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis. Clin Exp Allergy 2004;34:952-7
46. GlaxoSmithKline. Trial number: FNM30019; Available at: www.clinicalstudyresults.org. [Last accessed 24 April 2009]
47. Ortolani C, Foresi A, Di Lorenzo G, et al. A double-blind, placebo-controlled comparison of treatment with fluticasone propionate and levocabastine in patients with seasonal allergic rhinitis. FLNCO2 Italian Study Group. Allergy 1999;54:1173-80
48. Schering-Plough. Trial number: P03431; Available at: www. clinicalstudyresults. org. [Last accessed 24 April 2009]
49. Berkowitz RB, Roberson S, Zora J, et al. Mometasone furoate nasal spray is rapidly effective in the treatment of seasonal allergic rhinitis in an outdoor (park), acute exposure setting. Allergy Asthma Proc 1999;20:167-72
50. Bronsky EA, Aaronson DW, Berkowitz RB, et al. Dose ranging study of mometasone furoate (Nasonex) in seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997;79:51-6
51. Schering-Plough. Trial number: C92-011; Available at: www.fda.gov/cder/foi/nda. [Last accessed 24 April 2009]
52. Schering-Plough. Trial number: C93-013; Available at: www.fda.gov/cder/foi/nda. [Last accessed 24 April 2009]
53. Schering-Plough. Trial number: C93-184; Available at: www.fda.gov/cder/foi/nda. [Last accessed 24 April 2009]
54. Schering-Plough. Trial number: P04608; Available at: www. clinicalstudyresults.org. [Last accessed 24 April 2009]
55. Schering-Plough. Trial number: I94-001; Available at: www.fda.gov/cder/foi/nda. [Last accessed 24 April 2009]
56. Schering-Plough. Trial number: C94-145; Available at: www.fda.gov/cder/foi/nda. [Last accessed 24 April 2009]
57. Anolik R. Clinical benefits of combination treatment with mometasone furoate nasal spray and loratadine vs monotherapy with mometasone furoate in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2008;100:264-71
58. Schering-Plough. Trial number: P05067; Available at: www. clinicalstudyresults.org. [Last accessed 24 April 2009]
59. Prenner B, Shekar T, Teper A. Once-daily mometasone furoate nasal spray reduces ocular symptoms associated with seasonal allergic rhinitis. Presented at the XXVII Congress of the European Academy of Allergology and Clinical Immunology, Barcelona, Spain, June 7-11, 2008;Abstract 995
60. Schering-Plough. Trial number: P05106; Available at: www. clinicalstudyresults. org. [Last accessed 24 April 2009]
61. Hebert J, Danzig M, Gates D. Mometasone furoate improves total ocular symptom score in patients with allergic rhinitis. J Allergy Clin Immunol 2007;119[1 Suppl]:S61. Abstract 240
62. Munk ZM, Gross GN, Hampel Jr FC, et al. Preseasonal, once daily triamcinolone acetonide nasal aerosol for seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997;78:325-31
63. Settipane G, Korenblat PE, Winder J, et al. Triamcinolone acetonide aqueous nasal spray in patients with seasonal ragweed allergic rhinitis: a placebo-controlled, double-blind study. Clin Ther 1995;17:252-63
64. Bielory L. Ocular symptom reduction in patients with seasonal allergic rhinitis treated with the intranasal corticosteroid mometasone furoate. Ann Allergy Asthma Immunol 2008; 100:272-9
65. Schenkel E, LaForce C, Gates D. Mometasone furoate nasal spray in seasonal allergic rhinitis - Effective in relieving ocular symptoms. Allergy Clin Immunol Int 2007;19:50-3
66. Allen DB. Systemic effects of intranasal steroids: an endocrinologist's perspective. J Allergy Clin Immunol 2000; 106:S179-90
67. Passalacqua G, Albano M, Canonica GW, et al. Inhaled and nasal corticosteroids: safety aspects. Allergy 2000;55:16-33
68. Bernstein D. Long-term ocular safety of mometasone furoate nasal spray during treatment of perennial allergic rhinitis. Presented at the XXVII Congress of the European Academy of Allergology and Clinical Immunology, Barcelona, Spain, June 7-11, 2008;Abstract 194
69. Benninger MS, Ahmad N, Marple BF. The safety of intranasal steroids. Otolaryngol Head Neck Surg 2003;129:739-50
70. Allen A, Down G, Newlands A, et al. Tolerability, safety, pharmacokinetics and bioavailability of the novel intranasal corticosteroid fluticasone furoate in healthy subjects. Ann Allergy Asthma Immunol 2007;98:A89
71. Rosenblut A, Bardin PG, Muller B, et al. Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis. Allergy 2007;62:1071-7
72. Wagenmann M, Baroody FM, Desrosiers M, et al. Unilateral nasal allergen challenge leads to bilateral release of prostaglandin D2. Clin Exp Allergy 1996;26:371-8
73. Salter M, Biggadike K, Matthews JL, et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol 2007;293:L660-7
74. Valotis A, Högger P. Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate. Respir Res 2007;8:54